(Q37691240)

22 August 2017

1 reference

title

Angiotensin receptor blockers in hypertension. New insights from Japan (English)

1 reference

22 August 2017

main subject

arterial hypertension

0 references

1 reference

5

Gianpaolo Reboldi

1 reference

22 August 2017

Paolo Verdecchia

1

1 reference

22 August 2017

Fabio Angeli

series ordinal

2

1 reference

22 August 2017

Giovanni Mazzotta

series ordinal

3

1 reference

22 August 2017

Giuseppe Ambrosio

series ordinal

4

1 reference

22 August 2017

publication date

12 February 2010

1 reference

22 August 2017

published in

Hypertension Research

1 reference

22 August 2017

volume

33

1 reference

22 August 2017

issue

5

1 reference

22 August 2017

page(s)

394-397

1 reference

https://scigraph.springernature.com/pub.10.1038/hr.2010.13

22 August 2017

exact match

0 references

cites work

2007 Guidelines for the Management of Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Cardiovascular protection and blood pressure reduction: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Telmisartan to prevent recurrent stroke and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Angiotensin receptor blockers and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Angiotensin receptor blockers: baseline therapy in hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluati

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

7 January 2021

Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

7 January 2021

Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

7 January 2021

Do angiotensin II receptor blockers increase the risk of myocardial infarction?

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

7 January 2021

Thrombolytics for PE and right ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.13

7 January 2021

Identifiers

DOI

10.1038/HR.2010.13

1 reference

Dimensions Publication ID

22 August 2017

1000012017

0 references

1 reference